WO2005010049A3 - Tgf-beta1 ligands - Google Patents

Tgf-beta1 ligands Download PDF

Info

Publication number
WO2005010049A3
WO2005010049A3 PCT/US2004/018921 US2004018921W WO2005010049A3 WO 2005010049 A3 WO2005010049 A3 WO 2005010049A3 US 2004018921 W US2004018921 W US 2004018921W WO 2005010049 A3 WO2005010049 A3 WO 2005010049A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta1
tgf
ligands
reagents
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/018921
Other languages
French (fr)
Other versions
WO2005010049A2 (en
Inventor
Heidi Marie Bradley
Kristine Kay Kikly
Joanne Sloan Lancaster
Scott William Rowlinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to EP04776554A priority Critical patent/EP1646655A2/en
Publication of WO2005010049A2 publication Critical patent/WO2005010049A2/en
Publication of WO2005010049A3 publication Critical patent/WO2005010049A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Isolated and/or recombinant binding compositions, reagents related thereto are provided. Methods of using said reagents and diagnostic kits are also provided.
PCT/US2004/018921 2003-07-09 2004-07-06 Tgf-beta1 ligands Ceased WO2005010049A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04776554A EP1646655A2 (en) 2003-07-09 2004-07-06 Tgf-beta1 ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48582003P 2003-07-09 2003-07-09
US60/485,820 2003-07-09

Publications (2)

Publication Number Publication Date
WO2005010049A2 WO2005010049A2 (en) 2005-02-03
WO2005010049A3 true WO2005010049A3 (en) 2005-08-18

Family

ID=34102666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018921 Ceased WO2005010049A2 (en) 2003-07-09 2004-07-06 Tgf-beta1 ligands

Country Status (2)

Country Link
EP (1) EP1646655A2 (en)
WO (1) WO2005010049A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US12612453B2 (en) 2022-09-16 2026-04-28 Genzyme Corporation Method of treating glomerulonephritis by administering an antibody which binds and neutralizes human TGF-Beta1, TGF-Beta2 and TGF-Beta3

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7467175B2 (en) 2003-12-29 2008-12-16 Xilinx, Inc. Programmable logic device with pipelined DSP slices
US7467177B2 (en) 2003-12-29 2008-12-16 Xilinx, Inc. Mathematical circuit with dynamic rounding
US7480690B2 (en) 2003-12-29 2009-01-20 Xilinx, Inc. Arithmetic circuit with multiplexed addend inputs
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
ATE505489T1 (en) * 2005-04-22 2011-04-15 Lilly Co Eli TGF-BETA-1 SPECIFIC ANTIBODIES
JP2009521496A (en) * 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー TGF-β binding composition
ES2673822T3 (en) * 2006-07-18 2018-06-25 Sanofi Antagonist antibody against EphA2 for cancer treatment
DK2083863T3 (en) 2006-10-03 2015-06-22 Genzyme Corp ANTIBODIES AGAINST TGF-BETA TO USE IN TREATMENT OF BABIES WITH RISK OF DEVELOPMENT OF SOURCOPULMONAL DYSPLASY
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR20170012582A (en) 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Alk1 receptor and ligand antagonists and uses thereof
TWI672151B (en) 2008-05-02 2019-09-21 艾西利羅製藥公司 Methods and compositions for modulating angiogenesis and pericyte composition
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
EP2497782A1 (en) 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
CN110947002A (en) * 2012-05-01 2020-04-03 约翰霍普金斯大学 Compositions and methods for treating or preventing osteoarthritis
WO2014078373A1 (en) * 2012-11-13 2014-05-22 Iogenetics, Llc Antimicrobial compositions
BR112015023239A8 (en) 2013-03-14 2018-04-17 Abbott Lab hcv antibody-antigen combination assay and methods and compositions for use thereof
JP2016512241A (en) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ HCVNS3 recombinant antigen for improved antibody detection and mutants thereof
WO2015077540A2 (en) * 2013-11-21 2015-05-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
CN106794233B (en) 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 Compositions and methods relating to treatment of pulmonary hypertension
KR20180077181A (en) 2015-10-07 2018-07-06 오비아이 파머 인코퍼레이티드 Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
TWI788321B (en) 2017-01-20 2023-01-01 美商健臻公司 Bone-targeting antibodies
TW202506185A (en) 2017-01-20 2025-02-16 法商賽諾菲公司 Anti-tgf-beta antibodies and their use
ES2984919T3 (en) 2017-11-06 2024-10-31 Hoffmann La Roche Diagnostic and therapeutic procedures for cancer
JP2022527972A (en) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル How to predict and prevent cancer in patients with premalignant lesions
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013844A1 (en) * 1995-10-06 1997-04-17 Cambridge Antibody Technology Limited Specific binding members for human transforming growth factor beta; materials and methods
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013844A1 (en) * 1995-10-06 1997-04-17 Cambridge Antibody Technology Limited Specific binding members for human transforming growth factor beta; materials and methods
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELLINGSWORTH L R ET AL: "TRANSFORMING GROWTH FACTOR-BETAS ARE EQUIPOTENT GROWTH INHIBITORS OF INTERLEUKIN-1-INDUCED THYMOCYTE PROLIFERATION", CELLULAR IMMUNOLOGY, vol. 114, no. 1, 1988, pages 41 - 54, XP009042444, ISSN: 0008-8749 *
FLANDERS K C ET AL: "ANTIBODIES TO PEPTIDE DETERMINANTS IN TRANSFORMING GROWTH FACTOR BETA AND THEIR APPLICATIONS", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 27, 1988, pages 739 - 746, XP002044723, ISSN: 0006-2960 *
LUCAS C ET AL: "THE AUTOCRINE PRODUCTION OF TRANSFORMING GROWTH FACTOR-BETA1 DURING LUMPHOCYTE ACTIVATION A STUDY WITH A MONOCLONAL ANTIBODY-BASED ELISA", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 145, 1 September 1990 (1990-09-01), pages 1415 - 1422, XP000917385, ISSN: 0022-1767 *
Monoclonal anti-TGF-b1 antibody. R&D Systems, Ordering Information, Catalog Number: MAB2401, 29.1.2003. *
SHAH M ET AL: "NEUTRALISATION OF TGF-BETA1 AND TGF-BETA2 OR EXOGENOUS ADDITION OF TGF-BETA3 TO CUTANEOUS RAT WOUNDS REDUCES SCARRING", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 108, no. PART 3, 1 March 1995 (1995-03-01), pages 985 - 1002, XP000609005, ISSN: 0021-9533 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US12612453B2 (en) 2022-09-16 2026-04-28 Genzyme Corporation Method of treating glomerulonephritis by administering an antibody which binds and neutralizes human TGF-Beta1, TGF-Beta2 and TGF-Beta3

Also Published As

Publication number Publication date
EP1646655A2 (en) 2006-04-19
WO2005010049A2 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2005010049A3 (en) Tgf-beta1 ligands
WO2002090539A3 (en) Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
EP1623011A4 (en) IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2006020947A9 (en) Phosphonate fluorescent dyes and conjugates
WO2006058237A3 (en) Polymer-coated substrates for binding biomolecules and methods of making and using thereof
BRPI0608376A8 (en) binding composition, method of using a binding composition, and detection kit
WO2006009901A3 (en) Novel antigen-binding polypeptides and their uses
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2006028429A3 (en) Peptides for targeting the prostate specific membrane antigen
AU2003286588A1 (en) Methods for synthesizing complementary dna
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
WO2004013160A3 (en) Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2005062947A3 (en) Methods and compositions for identifying rna-binding proteins
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2005033133A3 (en) Polynucleotides encoding erbb-2 polypeptides and kits and methods using same
WO2005123913A3 (en) Reversibly modified thermostable enzyme compositions and methods of making and using the same
WO2004110365A3 (en) Liver related disease compositions and methods
WO2004063339A3 (en) G-quadruplex binding assays and compounds therefor
WO2003093434A3 (en) Nanoarchaeum nucleic acid molecule
WO2005035721A3 (en) Native immunoglobulin binding reagents and methods for making and using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004776554

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004776554

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004776554

Country of ref document: EP